PhD Timothy Vartanian MD

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Neutralizing antibodies (NAbs) can develop in a large proportion of patients with MS who receive treatment with interferon beta (IFNβ). Data show that IFNβ-1b is more immunogenic than IFNβ-1a and that IFNβ-1a-Rebif® is more immunogenic than IFNβ-1a-Avonex®. This article reviews the long-term data from large phase III clinical trials showing that NAbs can(More)
  • 1